HairClone co-founder and CEO, Dr Paul Kemp, was invited to deliver a talk at the AMC Meeting held at The Catalyst in Newcastle on 1st May 2025. The AMC (Advanced therapy medicinal products Manufacturing Community) was founded to develop a supportive community that shares best practices and enhances the development of cellular therapies and regenerative medicines (ATMPs).
Paul’s talk, titled “Flexible Manufacturing and Progressive Translation: A Case History”, discussed his decades of experience in taking novel cellular treatments from concept to product release. He used specific cases and personal experience to highlight key events and barriers, emphasising the importance of clinical study design and how patient selection can dictate success or failure in the clinical trial of an ATMP. Paul concluded his talk by explaining how relevant this experience has been to the ongoing clinical and commercial plans of HairClone.
The AMC conference attracts a range of professionals interested in advancing medicinal products into the clinic, including researchers, clinicians, regulators, and contract manufacturers. Among additional speakers were Dave Simpson from Iksuda Therapeutics, who spoke about antibody-drug conjugates, and Prof. Clare Selden from University College London, who presented on the potential of using ‘livers in a can’ to buy people time when experiencing liver damage.
The AMC was founded in 2010, when cell therapies were just emerging in the UK. Paul formed part of the initial advisory board, having played a pivotal role in developing the first cell therapies in the US and UK. It now has around 400 members that come together regularly to help to develop best practices, reduce barriers, and influence the regulatory landscape through a single, consistent voice.
